FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131335251> ?p ?o ?g. }

• W3131335251 endingPage "28" @default.
• W3131335251 startingPage "PS5" @default.
• W3131335251 abstract "Abstract Background: Three CDK 4/6 inhibitors (inh) are FDA approved in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC), however, there are no validated predictive markers of response to this class of drugs. Approximately 30-40% of patients (pts) have little to no response to these agents, with disease progression occurring in weeks to a few months after therapy initiation. We conducted an open-label, multicenter clinical trial (NCT03195192) to utilize cutting edge proteomic technologies to map the functional activation of the signaling architecture of pre-treatment tumor tissue from HR+/HER2- MBC pts receiving first line CDK4/6 inh plus ET, and to correlate these functional phosphoprotein-based signaling patterns with 1-year progression-free survival (1-yr PFS). Methods: We enrolled 29 of 100 planned pts, then the study closed early due to slow accrual. All pts were followed up to 12 months from starting a CDK4/6 inhibitor or until disease progression if it occurred earlier. The primary objective of this trial is to assess the correlation between baseline phosphorylated Rb levels that indicate activated Rb in tumor tissue and 1-yr PFS. We hypothesized that high levels of activated Rb will identify pts who are more likely to respond to CDK4/6 inh. Secondary objective is to evaluate the correlation between 1-yr PFS and 8 pre-specified qualifying (protein/phosphoprotein CDK 4/6 kinase pathway biomarkers: total Rb, Rb (S780), total Cyclin D1, Cyclin D1 (S286), total p16INK, total p27, p27 (T187), FoxM1 (T600). Results: Pre-treatment diagnostic FFPE biopsy material available from 24 evaluable pts were analyzed by a Laser Capture Microdissection (LCM) Reverse Phase Protein Microarray (RPPA) workflow. Seventeen of 24 pts (71%) were White, 7 (29%) African American; median age 65 (range 36-79); 22 pts (92%) received an aromatase inh and 2 (8%) had fulvestrant. The primary analysis expressed the relationship between phospho-RB and 1-yr PFS as a 2x2 table of frequencies summarized either above or below the median values observed in all pt values using a Pearson chi-squared test. Similarly, we analyzed the qualified protein/phosphoprotein markers quantified by RPPA by median dichotomization. Univariate analysis showed that 1-yr PFS correlated with below median levels of phospho and total RB (Chi-sq = 8.71, p-value = 0.003); phospho-FoxM1 (Chi-sq = 4.44, p-value = 0.035); Cyclin D1 S286 (Chi-sq = 4.44, p-value = 0.035); total and phospho-p27 and Ki67 (Chi-sq = 4.44, p-value = 0.035). None of these biomarkers were individually significant as continuous variables on multivariate analysis by logistic regression. Conclusions: Functional CDK 4/6 drug target pathway mapping analysis is possible from the pre-treatment diagnostic FFPE material. Our results indicate that pts whose tumors had low inherent proliferative and CDK 4/6 kinase activity were more likely to respond to first line CDK4/6 inh plus ET indicating possible prognostic determinants of the biomarkers. Citation Format: Maysa M Abu-Khalaf, Christos Hatzis, K. Alex Hodge, Frances Valdes, William Sikov, Monica Mita, Neelima Denduluri, Kris Awerkamp, Rita Murphy, Daniel Zelterman, Bryant Dunetz, Emanuel Petricoin, Mariaelena Pierobon. Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS5-28." @default.
• W3131335251 created "2021-03-01" @default.
• W3131335251 creator A5002120924 @default.
• W3131335251 creator A5006243393 @default.
• W3131335251 creator A5006654903 @default.
• W3131335251 creator A5023762376 @default.
• W3131335251 creator A5028833538 @default.
• W3131335251 creator A5039079551 @default.
• W3131335251 creator A5042026379 @default.
• W3131335251 creator A5042478245 @default.
• W3131335251 creator A5045617170 @default.
• W3131335251 creator A5067531125 @default.
• W3131335251 creator A5073337554 @default.
• W3131335251 creator A5076126973 @default.
• W3131335251 creator A5088946926 @default.
• W3131335251 date "2021-02-15" @default.
• W3131335251 modified "2023-10-02" @default.
• W3131335251 title "Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer" @default.
• W3131335251 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps5-28" @default.
• W3131335251 hasPublicationYear "2021" @default.
• W3131335251 type Work @default.
• W3131335251 sameAs 3131335251 @default.
• W3131335251 citedByCount "0" @default.
• W3131335251 crossrefType "journal-article" @default.
• W3131335251 hasAuthorship W3131335251A5002120924 @default.
• W3131335251 hasAuthorship W3131335251A5006243393 @default.
• W3131335251 hasAuthorship W3131335251A5006654903 @default.
• W3131335251 hasAuthorship W3131335251A5023762376 @default.
• W3131335251 hasAuthorship W3131335251A5028833538 @default.
• W3131335251 hasAuthorship W3131335251A5039079551 @default.
• W3131335251 hasAuthorship W3131335251A5042026379 @default.
• W3131335251 hasAuthorship W3131335251A5042478245 @default.
• W3131335251 hasAuthorship W3131335251A5045617170 @default.
• W3131335251 hasAuthorship W3131335251A5067531125 @default.
• W3131335251 hasAuthorship W3131335251A5073337554 @default.
• W3131335251 hasAuthorship W3131335251A5076126973 @default.
• W3131335251 hasAuthorship W3131335251A5088946926 @default.
• W3131335251 hasConcept C121608353 @default.
• W3131335251 hasConcept C124320809 @default.
• W3131335251 hasConcept C126322002 @default.
• W3131335251 hasConcept C143998085 @default.
• W3131335251 hasConcept C199835354 @default.
• W3131335251 hasConcept C2775930923 @default.
• W3131335251 hasConcept C2776694085 @default.
• W3131335251 hasConcept C2778822529 @default.
• W3131335251 hasConcept C2779744173 @default.
• W3131335251 hasConcept C2779786085 @default.
• W3131335251 hasConcept C29537977 @default.
• W3131335251 hasConcept C502942594 @default.
• W3131335251 hasConcept C530470458 @default.
• W3131335251 hasConcept C71924100 @default.
• W3131335251 hasConceptScore W3131335251C121608353 @default.
• W3131335251 hasConceptScore W3131335251C124320809 @default.
• W3131335251 hasConceptScore W3131335251C126322002 @default.
• W3131335251 hasConceptScore W3131335251C143998085 @default.
• W3131335251 hasConceptScore W3131335251C199835354 @default.
• W3131335251 hasConceptScore W3131335251C2775930923 @default.
• W3131335251 hasConceptScore W3131335251C2776694085 @default.
• W3131335251 hasConceptScore W3131335251C2778822529 @default.
• W3131335251 hasConceptScore W3131335251C2779744173 @default.
• W3131335251 hasConceptScore W3131335251C2779786085 @default.
• W3131335251 hasConceptScore W3131335251C29537977 @default.
• W3131335251 hasConceptScore W3131335251C502942594 @default.
• W3131335251 hasConceptScore W3131335251C530470458 @default.
• W3131335251 hasConceptScore W3131335251C71924100 @default.
• W3131335251 hasIssue "4_Supplement" @default.
• W3131335251 hasLocation W31313352511 @default.
• W3131335251 hasOpenAccess W3131335251 @default.
• W3131335251 hasPrimaryLocation W31313352511 @default.
• W3131335251 hasRelatedWork W2001196910 @default.
• W3131335251 hasRelatedWork W2130521606 @default.
• W3131335251 hasRelatedWork W2600199136 @default.
• W3131335251 hasRelatedWork W2934076975 @default.
• W3131335251 hasRelatedWork W3203106735 @default.
• W3131335251 hasRelatedWork W4229042453 @default.
• W3131335251 hasRelatedWork W4253790588 @default.
• W3131335251 hasRelatedWork W4379054559 @default.
• W3131335251 hasRelatedWork W4383618614 @default.
• W3131335251 hasRelatedWork W2342209702 @default.
• W3131335251 hasVolume "81" @default.
• W3131335251 isParatext "false" @default.
• W3131335251 isRetracted "false" @default.
• W3131335251 magId "3131335251" @default.
• W3131335251 workType "article" @default.